



Mereo Biopharma Group PLC Class Action Lawsuit - MREO

Mereo Biopharma Group PLC
NASDAQ: MREO

The *Mereo Biopharma Group PLC* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Mereo Biopharma Group PLC* ("Mereo") (NASDAQ: MREO) American Depositary Shares between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"). Captioned *Dodge v. Merco Biopharma Group PLC*, No. 26-cv-00988 (S.D.N.Y.), the *Mereo* class action lawsuit alleges that *Mereo* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you experienced losses as a result of your *Mereo* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than April 6, 2026.

CASE BACKGROUND:

Mereo is a biopharmaceutical company focused on the development of therapies for rare diseases. Its product candidate setrusumab is for the treatment of osteogenesis imperfecta, which is a rare genetic disorder that causes fragile bones.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) *Mereo* oversold setrusumab's efficacy by relying on earlier clinical data that did not support the statements being made about the subsequent clinical trials; (2) *Mereo* disregarded that neither of the subsequent trials would reach statistical significance against the primary endpoints of reducing fractures compared to the placebo; (3) the company failed to control for either the impacts of the standard of care nor of the placebo effect in the trials; (4) the methods of analyzing and predicting the trial results was based off of limited and incomplete data; and (4) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

THE LEAD PLAINTIFF PROCESS:

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Mereo* American Depositary Shares during the Class Period to seek appointment as lead plaintiff in the *Mereo* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will



Mereo Biopharma Group PLC Class Action Lawsuit - MREO

adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out our online form or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California.

